<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02920346</url>
  </required_header>
  <id_info>
    <org_study_id>13-1879</org_study_id>
    <nct_id>NCT02920346</nct_id>
  </id_info>
  <brief_title>Prospective Maternal Surveillance of SSA (Sjögren Syndrome A) Positive Pregnancies Using a Hand-held Fetal Heart Rate Monitor</brief_title>
  <official_title>Heart Sounds at Home: Prospective Maternal Surveillance of SSA Positive Pregnancies Using a Hand-Held Fetal Heart Rate Monitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's National Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stollery Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York Presbyterian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins All Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanford Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Virginia Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phoenix Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the research study &quot;Heart Sounds at Home&quot; is for pregnant SSA or SSA/SSB&#xD;
      (Sjögren syndrome B) antibody positive mothers to use a Doppler fetal heart rate monitor to&#xD;
      detect abnormal heart rates and rhythms in their babies before they are born.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll mothers during week 16-19 of gestation and will ask the mothers to use&#xD;
      a hand-held Doppler monitor to listen to the baby's heart rate and rhythm twice daily from&#xD;
      about week 16 to week 26 of the pregnancy. Pregnant mothers will be asked to keep a log of&#xD;
      the heart rates and will undergo a fetal echocardiogram every 2 weeks during their study&#xD;
      participation. In addition to these procedures, the study team will collect the mother's&#xD;
      medical and obstetrical histories. Should irregular heart rhythms be detected at home, the&#xD;
      mother will contact the investigator to be evaluated. After the baby is delivered, the study&#xD;
      team will collect information about the baby's birth and heart rhythm evaluation&#xD;
      (electrocardiogram).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">June 16, 2020</completion_date>
  <primary_completion_date type="Actual">June 16, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Fetal AV (atrio-ventricular) heart block</measure>
    <time_frame>Date of randomization until the date of first documented progression, assessed up to 41 weeks.</time_frame>
    <description>Development of fetal AV heart block will be determined by the principal investigator's analysis of the fetal echocardiogram.</description>
  </primary_outcome>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <condition>Neonatal Systemic Lupus Erythematosus</condition>
  <condition>Fetal Heart Block Complete</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include all pregnant women with positive SSA or SSA and SSB&#xD;
        antibodies between the gestational ages of 16-19 weeks with no signs of antibody-mediated&#xD;
        fetal cardiac disease on pre-enrollment fetal echocardiogram. Subjects who are more than 19&#xD;
        weeks gestation will not be included. Subjects who have a fetus with an estimated fetal&#xD;
        weight below the 10th percentile will also not be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women with positive SSA or SSA and SSB antibodies&#xD;
&#xD;
          -  Gestational age (GA) between 16 and 19 weeks&#xD;
&#xD;
          -  No signs of antibody-mediated fetal cardiac disease on pre-enrollment echo&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are more than 19 weeks gestation&#xD;
&#xD;
          -  Subjects who have a fetus with an estimated fetal weight below the 10th percentile&#xD;
             will also not be included&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bettina F Cuneo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.heartsoundsathome.com</url>
    <description>study website</description>
  </link>
  <reference>
    <citation>Cuneo BF, Strasburger JF, Niksch A, Ovadia M, Wakai RT. An expanded phenotype of maternal SSA/SSB antibody-associated fetal cardiac disease. J Matern Fetal Neonatal Med. 2009 Mar;22(3):233-8. doi: 10.1080/14767050802488220.</citation>
    <PMID>19330707</PMID>
  </reference>
  <reference>
    <citation>Cuneo BF, Lee M, Roberson D, Niksch A, Ovadia M, Parilla BV, Benson DW. A management strategy for fetal immune-mediated atrioventricular block. J Matern Fetal Neonatal Med. 2010 Dec;23(12):1400-5. doi: 10.3109/14767051003728237. Epub 2010 Apr 12.</citation>
    <PMID>20384469</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <last_update_submitted>June 21, 2021</last_update_submitted>
  <last_update_submitted_qc>June 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neonatal Systemic lupus erythematosus</keyword>
  <keyword>Sjogren's syndrome</keyword>
  <keyword>Fetal Atrioventricular Block</keyword>
  <keyword>Fetal Heart Block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Heart Block</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

